205676-84-2

Usage

Uses

Used in Scientific Laboratories:
(TERT-BUTOXY)-N-METHYL-N-[6-METHYL-(2-PYRIDINYL)]CARBOXAMIDE is used as a research compound for various scientific experiments and studies, contributing to the advancement of knowledge in chemistry and related fields.
Used in Academic Research:
(TERT-BUTOXY)-N-METHYL-N-[6-METHYL-(2-PYRIDINYL)]CARBOXAMIDE serves as a subject of investigation in academic research, potentially leading to new discoveries and applications in the chemical sciences.
Used in Pharmaceutical Production:
(TERT-BUTOXY)-N-METHYL-N-[6-METHYL-(2-PYRIDINYL)]CARBOXAMIDE is used as a potential component in the synthesis of pharmaceuticals, playing a role in the development of new drugs and medications.
Used as a Chemical Reaction Reagent:
In chemical reactions, (TERT-BUTOXY)-N-METHYL-N-[6-METHYL-(2-PYRIDINYL)]CARBOXAMIDE may be employed as a reagent, facilitating specific transformations and reactions in the synthesis of various compounds.

InChI:InChI=1/C11H16N2O2/c1-8-6-5-7-9(12-8)13-10(14)15-11(2,3)4/h5-7H,1-4H3,(H,12,13,14)

Upstream product

• 90101-22-7 2-(tert-butoxycarbonylamino)-6-picoline 
• 74-88-4 methyl iodide 
• 1824-81-3 2-Amino-6-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 78782-17-9 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane 

Downstream Products

• 1292954-98-3 C₂₅H₃₆N₄O₅ 
• 959991-22-1 methyl O-({6-[(tert-butoxycarbonyl)(methyl)amino]pyridin-2-yl}methyl)-N-(2,6-dichlorobenzoyl)-L-tyrosinate 
• 205678-31-5 (4S)-2,3,4,5-tetrahydro-8-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-1H-2-benzazepine-4-acetic acid 
• 474658-53-2 ethyl 5-(3-{2-[6-(methylamino)(2-pyridyl)]ethoxy}phenoxy)-4-oxopentanoate 
• 474658-52-1 [6-(2-{3-[1,1-bis(methylethyl)-2-methyl-1-silapropoxy]phenoxy}ethyl)(2-pyridyl)]methylamine 
• 205676-86-4 ethyl 2-[6-(methylamino)-2-pyridyl]acetate 
• 205676-87-5 2-methylamino-6-(2-hydroxyethyl)pyridine 

Relevant academic research and scientific papers

Transition-Metal-Free Regioselective Alkylation of Pyridine N-Oxides Using 1,1-Diborylalkanes as Alkylating Reagents

Reported herein is an unprecedented base-promoted deborylative alkylation of pyridine N-oxides using 1,1-diborylalkanes as alkyl sources. The reaction proceeds efficiently for a wide range of pyridine N-oxides and 1,1-diborylalkanes with excellent regioselectivity. The utility of the developed method is demonstrated by the sequential C?H arylation and methylation of pyridine N-oxides. The reaction also can be applied for the direct introduction of a methyl group to 9-O-methylquinine N-oxide, thus it can serve as a powerful method for late-stage functionalization.

Synthesis and structure–activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of β-amyloid-42 aggregation

It is assumed that amyloid-β aggregation is a crucial event in the pathogenesis of Alzheimer's disease. Novel 2,6-disubstituted pyridine derivatives were designed to interact with the β-sheet conformation of Aβ via donor–acceptor–donor hydrogen bond forma

2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

2,6-Diaminopyridine Compounds Suitable For Treating Diseases Associated With Amyloid Or Amyloid-Like Proteins Or For Treating Or Preventing Ocular Diseases Or Conditions Associated With A Pathological Abnormality/Change In The Tissue Of The Visual System

The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun

Facile preparation of thiophene C2-ethers using the Mitsunobu reaction

The preparation of thiophene ethers generally requires forcing conditions thus limiting the choice of alkyl substituent. Herein, we report the first successful generally applicable conditions for the selective O-alkylation of 2(5H)-thiophenone.

Design, synthesis, and biological evaluation of novel potent and selective αvβ3/αvβ5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core

A novel series of potent and selective αvβ 3/αvβ5 dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the gua

PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES

Disclosed is a new process and intermediates for preparing benzazepines of Formula wherein R1 and R2 are as defined herein.

VITRONECTIN RECEPTOR ANTAGONISTS

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis wherein R is Het- or Ar; R is formula (a) or formula (b); or a pharmaceutically acceptable salt thereof.

Vitronectin receptor antagonists

Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.